Navigation Links
ResMed Inc. Announces Record Financial Results for the Quarter Ended and Nine Months Ended March 31, 2011

SAN DIEGO, April 28, 2011 /PRNewswire/ -- ResMed Inc. (NYSE: RMD) today announced record revenue and income for the quarter ended March 31, 2011.  Revenue for the quarter ended March 31, 2011 was $313.3 million, a 12% increase (also a 12% increase on a constant currency basis) over the quarter ended March 31, 2010.  For the quarter ended March 31, 2011, income from operations was $64.0 million and net income was $53.4 million, an increase of 5% and 9%, respectively, compared to the quarter ended March 31, 2010.  Diluted earnings per share for the quarter ended March 31, 2011 were $0.34, an increase of 10% compared to the quarter ended March 31, 2010.  


SG&A expenses were $92.5 million for the quarter ended March 31, 2011, an increase of $8.4 million, or 10% (an 8% increase on a constant currency basis) compared to the quarter ended March 31, 2010.  SG&A costs were 29.5% of revenue in the quarter ended March 31, 2011, compared to 30.2% for the quarter ended March 31, 2010.R&D expenses were $23.3 million for the quarter ended March 31, 2011, or 7.4% of revenue.  R&D expenses increased by 28% (an 18% increase on a constant currency basis) compared to the quarter ended March 31, 2010.  R&D expenses were negatively impacted by the appreciation of the Australian dollar against the U.S. dollar.

The company amortized acquired intangibles of $2.7 million ($1.8 million, net of tax) during the quarter ended March 31, 2011.  Stock-based compensation costs incurred during the quarter ended March 31, 2011 of $6.8 million ($4.8 million, net of tax) consisted of expenses associated with stock options, restricted stock units, and our employee stock purchase plan.  

For the nine months ended March 31, 2011, revenue was $901.3 million, an increase of 13% over the nine months ended March 31, 2010 (a 14% increase on a constant currency basis).  For the nine months ended March 31, 2011, income from operations and net income were $200.2 million and $168.5 million, an increase of 17% and 23%, respectively, compared to the nine months ended March 31, 2010.  Diluted earnings per share for the nine months ended March 31, 2011 were $1.07 per diluted share, an increase of 20% compared to the nine months ended March 31, 2010.

Inventory, at $205.0 million, increased by $19.4 million compared to June 30, 2010.  Accounts receivable days sales outstanding, at 68 days, decreased by 3 days compared to June 30, 2010.  

Peter C. Farrell PhD, Chairman and Chief Executive Officer, commented, "In the third quarter of fiscal 2011 we continued to show strong year-over-year growth especially in Europe and the Asia-Pacific region.  Revenue outside the Americas increased by 16% to $152.7 million over the prior year's quarter, or a 15% increase on a constant currency basis.
Revenue in the Americas increased by over 9% to $160.5 million over the prior year's quarter. Americas' revenues continued to be adversely impacted by reduced bilevel sales, but we expect that the recent launch of the S9™ bilevel series will help to reverse this trend. Worldwide, our growth in flow generators was mainly driven by sales of the S9 AutoSet™.  Patient interface sales did extremely well in all regions. With the recent launches of the Quattro™ FX full face mask and the Mirage™ FX nasal mask, we have completed the release of the trilogy of masks in the FX series.  Operating profit for the March quarter was $64.0 million and cash flow from operations was a record $81.4 million, demonstrating excellent operating performance.

"We expect the growth of all our products to continue to benefit from the vastly under-penetrated and growing sleep-disordered breathing market.  Due to the strong correlation between sleep-disordered breathing and comorbidities, such as heart disease and diabetes, chronic obstructive pulmonary disease, perioperative death and occupational health and safety, we believe that there are significant opportunities to further penetrate the market. In addition, findings from clinical studies continue to demonstrate the importance of diagnosing and treating sleep-disordered breathing.  Increasingly, there is evidence coming to light that early intervention in the treatment of sleep-disordered breathing may slow or prevent the progression of chronic diseases."

About ResMedResMed is a global leader in the development, manufacturing and marketing of medical products for the diagnosis, treatment and management of respiratory disorders, with a focus on sleep-disordered breathing. The company is dedicated to developing innovative products to improve the lives of those who suffer from these conditions and to increasing awareness among patients and healthcare professionals of the potentially serious health consequences of untreated sleep-disordered breathing. For more information on ResMed, visit

ResMed will host a conference call at 1:30 p.m. US Pacific Time today to discuss these quarterly results.  Individuals wishing to access the conference call may do so via ResMed's Website at or by dialing 617-614-4910 (domestic) or +1 617-614-4910 (international) and entering conference pass code no. 57596192. Please allow extra time prior to the call to visit the Website and download the streaming media player (Windows Media Player) required to listen to the Internet broadcast.  The online archive of the broadcast will be available approximately 90 minutes after the live call and will be available for two weeks.  A telephone replay of the conference call is available by dialing 617-801-6888 (domestic) and +1 617-801-6888 (international) and entering conference I.D. No. 68716093.

Further information can be obtained by contacting Constance Bienfait at ResMed Inc., San Diego, at (858) 836-5971; Brett Sandercock at ResMed Limited, Sydney, on (+612) 8884-2090; or by visiting the Company's multilingual Website at  

Statements contained in this release that are not historical facts are "forward-looking" statements as contemplated by the Private Securities Litigation Reform Act of 1995. These forward-looking statements, including statements regarding the Company's future revenue, earnings or expenses, new product development and new markets for the Company's products, are subject to risks and uncertainties, which could cause actual results to materially differ from those projected or implied in the forward-looking statements. Those risks and uncertainties are discussed in the Company's Annual Report on Form 10-K for its most recent fiscal year and in other reports the Company files with the U.S. Securities & Exchange Commission.  Those reports are available on the Company's Website.RESMED INC AND SUBSIDIARIESCondensed Consolidated Statements of Income (Unaudited)

(In US$ thousands, except per share data)Three Months Ended

March 31,

Nine Months Ended

March 31,2011



2010Net revenue




$800,785Cost of sales




319,819Gross profit




480,966Operating expenses:Selling, general and administrative




244,984Research and development




55,252Amortization of acquired intangible assets




5,967Donation to Foundation




3,000Total operating expenses




309,203Income from operations




171,763Other income (expenses), net:Interest income (expense), net




9,383Other, net




7,515Total other income (expenses), net




16,898Income before income taxes




188,661Income taxes




51,742Net income




$136,919Basic earnings per share




$0.91Diluted earnings per share




$0.89Basic shares outstanding




150,648Diluted shares outstanding




154,528All share and per share information has been adjusted to reflect the two-for-one stock split effected in the form of a 100% stock dividend that was declared on August 5, 2010 and distributed on August 30, 2010.

RESMED INC AND SUBSIDIARIESCondensed Consolidated Balance Sheets (Unaudited)

(In US$ thousands except share and per share data)March 31,

June 30,2011

2010ASSETSCurrent assets:Cash and cash equivalents


$488,776Accounts receivable, net




185,642Deferred income taxes


14,112Income taxes receivable


5,317Prepaid expenses and other current assets


64,583Total current assets


985,341Property, plant and equipment, net




198,625Other intangibles


30,925Deferred income taxes


19,042Other assets


5,316Total non-current assets


641,056Total assets


$1,626,397LIABILITIES AND STOCKHOLDERS' EQUITYCurrent liabilities:Accounts payable


57,535Accrued expenses


80,883Deferred revenue


29,507Income taxes payable


22,656Deferred income taxes


402Current portion of long-term debt


121,689Total current liabilities


312,672Non-current liabilities:Deferred income taxes


10,793Deferred revenue


12,755Income taxes payable


2,641Non Current portion of long-term debt


0Total non-current liabilities


26,189Total liabilities


338,861STOCKHOLDERS' EQUITY:Common stock


605Additional paid-in capital


660,185Retained earnings


884,876Treasury stock


(344,505)Accumulated other comprehensive income


86,375Total stockholders' equity


1,287,536Total liabilities and stockholders' equity



SOURCE ResMed Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. ResMed Acquires Laboratoires Narval
2. ResMed Inc Announces Record Financial Results for the Quarter and Six Months Ended December 31, 2009
3. ResMed Inc. Announces Record Financial Results for the Quarter Ended September 30, 2009
4. ResMed Inc. to Present at Upcoming Conferences
5. ResMed Announces Deferred Conversions in Connection With Stock Split
6. ResMed Inc. Announces Completion of Two-for-One Stock Split
7. Study Shows ResMeds New CPAP Device Increases Patient Compliance
8. ResMed Announces Conference Call and Webcast to Discuss First Quarter 2011 Results
9. ResMed Inc. Announces Record Financial Results for the Quarter Ended September 30, 2010
10. ResMed Announces Conference Call and Webcast to Discuss Second Quarter 2011 Results
11. ResMed Inc. Announces Record Financial Results for the Quarter Ended and Six Months Ended December 31, 2010
Post Your Comments:
(Date:10/9/2015)... , Oct. 9, 2015 Henry ... largest provider of health care products and services to ... its customers that the Henry Schein Disaster Relief Hotline ... operational, logistical or financial issues as a result of ... . The toll-free number for all Henry Schein ...
(Date:10/9/2015)... 9, 2015  Impax Laboratories, Inc. (NASDAQ: IPXL ... third quarter 2015 financial results on Monday, November 9, ... markets. The Company will host a conference call and ... Eastern Time on November 9, 2015.  ... The financial results and live webcast will be ...
(Date:10/9/2015)... Eli Lilly and Company (NYSE: LLY ) today announced ... jobs to its research and development presence at the Alexandria ... . --> --> ... translational immuno-oncology hub and a Lilly "portal," which will provide ... drug discovery capabilities, including chemistry and lead optimization expertise. ...
Breaking Medicine Technology:
... Society for Cardiovascular Angiography and Interventions (SCAI) 2011 Scientific ... measure and improve quality in the cath lab for ... of using evidence to guide new ways to advance ... quality program with its signature "Quality Improvement Toolkit" to ...
... Bank Pharmaceuticals today announced it has been awarded an ... Institute of Allergy and Infectious Diseases for the development ... treatment of Hepatitis B virus infection.   Under ... $3.9 million over five years in support of its development ...
Cached Medicine Technology:
(Date:10/9/2015)... ... 09, 2015 , ... The American Osteopathic Foundation (AOF) has ... Education J. Michael Finley, DO, as the recipient of the 2015 W. Douglas ... on graduate medical education opportunities for osteopathic residents, and his dedication to promoting ...
(Date:10/9/2015)... (PRWEB) , ... October 09, 2015 , ... "My spouse ... our canes falling when leaned against something," said an inventor from Buffalo, N.Y. "This ... cane users face daily." , The CANE REST enables a user to keep a ...
(Date:10/9/2015)... ... October 09, 2015 , ... Matrix IT Medical ... specifications for TRACTUS, the world’s first sterile field scanner. , The ... to the FDA’s recent Unique Device Identifier (UDI) Final Rule, which will require ...
(Date:10/9/2015)... , ... October 09, 2015 , ... "As a nurse, ... inventors from Philadelphia, Pa. "They have to wear large diapers or pads. We came ... They developed the TROUSAFE to absorb urine leaking from the tip of the penis. ...
(Date:10/9/2015)... ... October 09, 2015 , ... Ryan Fox, ... largest recreational dispensaries in Colorado, says the latest figures on the state’s sales ... maturing into a legitimate industry. , Last month, according to the ...
Breaking Medicine News(10 mins):
... University researcher will receive a $2.3 million New Innovator ... of synthetic platelets and the technology that makes them ... uses nanotechnology to build platelets of biodegradable polymers, which ... She and fellow researchers initially pursued the technology ...
... (Boston) - Boston Medical Center (BMC) has been awarded ... Heart, Lung and Blood Institute (NHLBI) for investigators from ... Center for Health Insurance Reform, Cardiovascular Outcomes and Disparities. ... understand the effects of Massachusetts health reform on cardiovascular ...
... Reporter , WEDNESDAY, Sept. 29 (HealthDay News) -- Another study ... screening can lower the risk of dying from breast cancer ... Sweden, found that women who were screened cut their risk ... over a 10-year period would save one life, study author ...
... by principal investigator Kang Zhang, MD, PhD, professor of ... Eye Center and director of UCSD,s Institute of Genomic ... NIH Transformative Award. Zhang and co-principal investigators Sheng ... Reh, PhD from the University of Washington, received the ...
... of immunotherapy to children with neuroblastoma, a nervous system ... and free of disease progression after two years, according ... School of Medicine and fellow institutions. The percentage rose ... to 66 percent for children receiving immunotherapy plus standard ...
... - Patients with triple negative breast cancer that also have ... risk of recurrence, compared to those with the same disease ... University of Texas MD Anderson Cancer Center. The findings ... this select group of triple negative breast cancer patients, as ...
Cached Medicine News:
... general purpose incubators designed to ... and uniformity required for the ... versatile microprocessor controlled incubators feature ... easy-to-read digital display, and built-in ...
... Economy Incubators available in five different models. ... 1.4 cu. Ft. (39 liters), 2.5 cu. ... (129 liters. Equally important, Precision Economy Incubators ... temperature sensitivity, stability, and uniformity. As a ...
... five different models. Choose mechanical or gravity ... liters), 2.5 cu. Ft. (71.5 liters), or ... Precision Economy Incubators combine a wide temperature ... uniformity. As a result, you will find ...
Binocular indirect ophthalmic lenses. Small pupil diagnosis & treatment....
Medicine Products: